Here's why the Proteomics International (ASX:PIQ) share price is halted

The shares in the medical technology company were last trading at 99.5 cents.

| More on:
pause in medical asx share price represented by doctor holding hand up in stop motion

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Proteomics International Laboratories Ltd (ASX: PIQ) share price won't be going anywhere today.

Shares in the biotech company were placed in a trading halt late yesterday.

Let's take a look at why the company's shares are at a halt and what it means for the Proteomics share price.

Proteomics share price halted on conference abstract

Securities in Proteomics were placed in a trading halt yesterday at the request of the company.

In a news release, the company noted that a trading halt was requested pending the release of the conference abstract.

Proteomics highlighted that the abstract outlines key findings from its second stage collaborative study to target treatment of diabetic kidney disease (DKD).

The abstract will be jointly presented by Janssen Research and Proteomics at the Australasian Diabetes Congress in mid-August.

Proteomics noted that the trading halt will remain until either a new announcement or until the commencement of trading on Friday, 16 July.

The Proteomics share price was last trading at 99.5 cents before entering a trading halt.

Snapshot of the Proteomics share price

Proteomics is a medical technology company that operates in predictive diagnostics and bioanalytical services. The company specialises in the area of proteomics which relates to the structure and function of proteins.

Proteomics' business model revolves around the commercialisation of its flagship PromarkerD product. PromarkerD functions by using a blood test to detect early onset of DKD in patients with type 2 diabetes. According to Proteomics, early detection is key in reducing the need for expensive treatment at later stages of the disease.

In previous clinical trials, it was reported that PromarkerD had 86% accuracy in predicting the number of patients that would develop CKD.

Proteomics also uses its Promarker technology platform to create a pipeline of novel diagnostic tests. The company recently received ISO 13485 certification which provides the foundation for manufacturing requirements.

The Proteomics share price has performed strongly in 2021, trading more than 26% higher since the start of the year. On a 52-week timeline, the Proteomics share price is more than 112% higher.

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Two smiling work colleagues discuss an investment or business plan at their office.
Broker Notes

Which beaten down ASX 200 share did Goldman Sachs just upgrade to a buy rating?

The broker has become more bullish on this stock following last week's update.

Read more »

Hand holding Australian dollar (AUD) bills, symbolising ex dividend day. Passive income.
Best Shares

The best ASX shares to invest $1,000 in right now

Analysts think that putting your money into these stocks could be a smart move.

Read more »

green etf represented by letters E,T and F sitting on green grass
Share Market News

4 ASX ETFs to buy for FY25 and beyond

Could these ETFs be top options for investors looking for long term picks?

Read more »

A smiling woman sips coffee at a cafe ready to learn about ASX investing concepts.

How I'd invest $10,000 in ASX shares right now

I’m bullish about the prospects of these stocks.

Read more »

A fortune teller looks into a crystal ball in an office surrounded by business people.
Share Market News

What's the outlook for shares vs. property in FY25?

Generally speaking, there is optimism among the experts for both shares and property in FY25.

Read more »

Happy shareholders clap and smile as they listen to a company earnings report.
Best Shares

Top ASX shares to buy before earnings season

It's almost time to take a look at the books!

Read more »

sad party goer sitting alone after celebration
Share Market News

Here are the top 10 ASX 200 shares today

The ASX 200 had a horrible end to its trading week this Friday.

Read more »

A young female investor sits in her home office looking at her ipad and smiling as she sees the QBE share price rising
Broker Notes

3 ASX shares brokers tip for significant outperformance in FY 2025

Leading brokers expect some significant outperformance from these three ASX shares.

Read more »